# Research Status and Progress of Third-generation EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer

## TL;DR

Third-generation EGFR-TKIs are effective and safe in elderly patients with NSCLC, with similar benefits to younger patients.

## Contribution

This study evaluates the efficacy and safety of third-generation EGFR-TKIs in elderly NSCLC patients using clinical trial data.

## Key findings

- Third-generation EGFR-TKIs show comparable efficacy in elderly and younger NSCLC patients.
- Combination therapies improve survival but increase toxicity in elderly patients.
- Safety profiles of third-generation EGFR-TKIs are favorable in elderly populations.

## Abstract

对于表皮生长因子受体（epidermal growth factor receptor, EGFR）敏感突变的晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）患者，指南优先推荐第三代EGFR-酪氨酸激酶抑制剂（EGFR-tyrosine kinase inhibitors, EGFR-TKIs），其客观缓解率（objective response rate, ORR）更高、无进展生存期（progression-free survival, PFS）更长且生活质量更优。然而，老年患者因临床试验入组比例较低，现有证据难以完全指导该人群的临床实践。本文通过整合前瞻性及回顾性研究中的亚组分析或预先指定的研究目的，探讨第三代EGFR-TKIs单药或联合治疗在老年NSCLC人群中的疗效与安全性差异。结果显示，第三代EGFR-TKIs在老年患者中疗效与年轻患者中相当且安全性良好。联合方案虽能延长生存期，但毒性叠加，需权衡风险。

Phase III clinical trials of third-generation EGFR-TKIs monotherapy for NSCLC

Phase I or II clinical trials of third-generation EGFR-TKIs monotherapy for NSCLC

Clinical trial of third-generation EGFR-TKIs combination therapy for NSCLC